IntelGenx Ships CBD Filmstrips to Heritage Cannabis in Support of Canadian Market Launch

SAINT LAURENT, Quebec, Aug. 31, 2021 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that it has completed an initial shipment of CBD Filmstrips in support of Heritage Cannabis Holdings Corp.’s (“Heritage Cannabis”) (CSE:CANN) Canadian market launch of its “CB4 Control” branded product.

The CBD Filmstrips were produced at IntelGenx’s manufacturing facility under Canadian GPP conditions and registered as a product for sale with Health Canada as a cannabis product governed by the Cannabis Act.

Dr. Horst G. Zerbe, CEO of IntelGenx, commented, “Our partnership with Heritage Cannabis paved the way for our recent transition from a development-stage to a commercial-stage company. We are looking forward to continuing to work with Heritage Cannabis to make innovative and high-quality oral thin film products available to medical cannabis consumers.”

“We are proud that the CB4 Control filmstrips, based on IntelGenx’s Versafilm^® platform, help comprise our new Opticann suite of branded products,” commented Umar Syed, President of the Medical Division at Heritage Cannabis. “We continue to believe the future of the oral cannabinoid market will be dominated by products based on innovative technologies such as VersaFilm^® that are proven to deliver rapid and better absorption in a convenient dosage form.”

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm^®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx’ operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’ plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “may,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “could,” “would,” and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’ actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading “Risk Factors” in IntelGenx’ annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQB has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com

Or

Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com